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The aim of this study was to quantify the variation in doses to organs at risk (ipsilateral lung and heart) and the
clinical target volume (CTV) in the presence of breast implants. In this retrospective cohort study, patients were
identified through the National Breast Cancer Register. Consecutive breast cancer patients undergoing mastectomy
between 2009 and 2011 and completing a full course of postmastectomy radiotherapy (PMRT) were eligible. All
included patients (n = 818) were identified in the ARIA© oncology information system and further stratified for
immediate breast reconstruction (IBR+, n = 162) and no immediate breast reconstruction (IBR-, n = 656). Dose
statistics for ipsilateral lung, heart and CTV were retrieved from the system. Radiation plans for patients with chest
wall (CW) only (n = 242) and CW plus lymph nodes (n = 576) irradiation were studied separately.
The outcome variables were dichotomized as follows: lung, V20Gy ≤ 30% vs. V20Gy > 30%; heart, Dmean ≤ 5 Gy
vs. Dmean > 5 Gy; CTV, V95% ≥median vs. V95% < median.
In the univariate and multivariate regression models no correlation between potential confounders (i.e. breast
reconstruction, side of PMRT, CW index) and the outcome variables was found. Multivariate analysis of CW plus
lymph nodes radiation plans, for example, showed no association of breast reconstruction with dosimetric
outcomes in neither lung nor heart- lung V20Gy (odds ratio [OR]: 0.6, 95%CI, 0.4 to 1.0, p = 0.07) or heart Dmean
(OR: 1.2, 95%CI, 0.5 to 3.1, p = 0.72), respectively.
CTV was statistically significantly larger in the IBR+ group (i.e. included breast implant), but no correlation between the
implant type and dosimetric characteristics of the organs at risk was revealed.
In the current study, the presence of breast implants during postmastectomy radiotherapy was not associated with
increased doses to ipsilateral lung and heart, but CTV definition and its dosimetric characteristics urge further evaluation.Background
Postmastectomy radiotherapy (PMRT) is shown to reduce
the risk of local recurrence and overall mortality in patients
with node-positive breast cancer [1]. Recent evidence that
radiotherapy (RT) is beneficial for patients with one to
three involved nodes or with high-risk node-negative dis-
ease has extended the application of PMRT [2,3].
Women operated on with total mastectomy are potential
candidates for a breast reconstruction [4]. The numbers of* Correspondence: dmytro.unukovych@ki.se
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stated.immediate breast reconstructions (IBRs) have increased
steadily [5,6] with the predominance of the implant based
techniques today [7].
In three dimensional computer-tomography based
(3DCT) PMRT planning, among all the OARs, heart
and lungs are the structures most difficult to protect.
RT was shown to cause a variety of radiation-induced
changes in heart (e.g. coronary artery disease, cardio-
myopathy, conduction disorders) and the risk of cor-
onary events linearly increases with the mean dose to
the heart [8,9]. One of the most common RT-induced
reactions in lung is radiation pneumonitis that corre-
lates with the dose distribution in the lung [10,11].
The presence of an implant implies a displacement ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tially increase lung and heart irradiation [12].
Two recent studies from the same institution con-
cluded that excellent chest wall radiation coverage, local
control and acceptable doses to risk organs could be
achieved in the presence of breast implants during in-
tensity modulated radiation therapy (IMRT) [13,14].
To our knowledge, no studies have assessed the im-
pact of breast implants on dose distribution in a large
cohort of patients after mastectomy undergoing conven-
tional tangential radiotherapy.
The aim of this study was to quantify the variation in
doses to organs at risk (ipsilateral lung and heart) and
the target volume in the presence of breast implants.
Patients and methods
Study population
The Swedish National Breast Cancer Register was used for
patient identification, and all women diagnosed with breast
cancer and operated on with total mastectomy within the
Stockholm-Gotland area between January 1 2009 and
December 31 2011 and receiving postmastectomyFigure 1 Study population, eligibility and inclusion/exclusion.radiotherapy were eligible. Data on type and date of breast
cancer surgery, tumor characteristics (laterality, size and
lymph nodes) and planned treatment characteristics
(radiotherapy, chemotherapy, endocrine therapy, and im-
munotherapy) were obtained from the registry. Subse-
quently, these patients were identified in the ARIA©
(Varian Medical Systems, Palo Alto, California)- an oncol-
ogy information system prospectively maintained at two
RT units at Karolinska University Hospital. Individual in-
formation on dates of radiotherapy (start and end), target
volume (chest wall or chest wall plus lymph nodes), total
dose, number of fractions, boost and bolus (if any), were
retrieved from the RT charts in ARIA©.
The inclusion criteria were patients undergoing mast-
ectomy as their primary surgery for breast cancer and
completing a full course of PMRT to ipsilateral chest
wall +/- regional lymph nodes.
Patients were excluded for the following reasons (Figure 1):
1) No radiotherapy performed de facto.
2) Radiotherapy to other than ipsilateral chest wall or
chest wall plus lymph nodes target area as some
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and/or axillary lymph nodes only.
3) No dosimetric data available in the verification
system, i.e. RT was given elsewhere or has not
started within the study period.
4) Radiotherapy course with a fractionation different
than 2 Gy in 25 fractions.
5) Misclassified patients, e.g. treated with breast
conservation therapy or those receiving RT to
contralateral side, or when changes in adjuvant
treatment plan ruled out PMRT.Target volume definition and radiotherapy technique and
planning
All patients received full course of RT at one of the units, ei-
ther at the Karolinska University Hospital in Solna (n = 425)
or at the Southern Hospital (n = 393), Stockholm, Sweden.
When CW only was included in the CTV the treatment
technique consisted of two tangential fields. For those cases
where the CTV included the lymph nodes, an isocentric
technique was used, consisting of tangential fields covering
CW and usually three fields covering the lymph nodes in
the supraclavicular fossa and in the axillary regions. Accord-
ing to the institution’s local practice, internal mammary
nodes (IMNs) were not specifically targeted. Both in the
treatment of the chest wall and in the treatment of the chest
wall plus lymph nodes field-in-field solutions were applied
where necessary [15].
Conventional tangential external-beam radiotherapy
with 6-MV photons was used in all cases, some pa-
tients also received additional 15-MV (n = 56, 6.8%) or
18-MV (n = 21, 2.6%) photon fields. Total prescribed
dose was 50 Gy in 2 Gy daily fractions. Additional
boost dose to the mastectomy scar, bolus, or a combin-
ation was utilized in 24 (3.0%), 31 (3.9%), and 3 (0.4%)
cases, respectively.Figure 2 Breast implants (from left to right): temporary expander (typ3D CT-based radiation treatment planning was per-
formed using the Varian Medical System Platform soft-
ware (Varian Medical Systems Inc., Palo Alto, USA).
Ipsilateral lung was contoured using auto-outline tool,
whereas heart and clinical target volume (CTV) were de-
lineated manually according to the RTOG guidelines.
CTV was defined as chest wall only (CW) for local
radiotherapy plans or CW plus lymph nodes (i.e. axillary,
infraclavicular and supraclavicular) for loco-regional
radiotherapy. In patients with IBR, CTV was always de-
lineated comprising the breast implant. Planning target
volume was defined by adding 5-7 mm margin around
CTV. Clinical protocols for radiotherapy planning were
the same during the study period.
Dose calculations were performed with the Eclipse
Treatment Planning System using the Analytical
Anisotropic Algorithm, AAA (Varian). The dose was pre-
scribed so that the CTV would be encompassed between
95% and 105% isodoses. According to the local proto-
cols the constraints to the ipsilateral lung was V20Gy (%
of volume receiving 20 Gy) <30%. The constraints to the
heart were mean dose < 5 Gy, V25Gy <10%, and normal tis-
sues complications probability (NTCP) <1% [16,17].Implant characteristics and localization
Three types of implants were used during the study
period (Figure 2 and Figure 3): type I, temporary ex-
panders with a single lumen and an integrated magnetic
port at the center of the implant for postoperative ex-
pansion; type II, expandable implants that are designed
for a definitive one-stage breast reconstruction. They
contain an outer chamber with silicon gel and a smaller
inner chamber that may be inflated postoperatively with
saline via the remote injection port placed subcutane-
ously on the chest wall; type III, permanent implants
filled with silicon gel with a predefined volume.e I), expandable implant (type II), permanent implant (type III).
Figure 3 Radiotherapy plan with: A. Temporary expander with magnet (type I), B. Expandable implant (type II), C. Permanent implant
(type III).
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plants were placed under total muscular coverage on the
chest wall. No acellular dermal matrices have been used
during the study period. In patients with expandable im-
plants, the gradual expansion was performed in several
sessions taking into consideration covering tissues.
Currently we avoid using expanders with the inte-
grated magnetic ports in patients that are likely to re-
ceive PMRT. Potential problems with the magnetic port
include difficulties in imaging (Figure 3a) [18,19] and
cause perturbation in dose distribution around the mag-
net [20-22]. In the current study, we did not focus on
these issues and thus excluded this subgroup from the
CTV dosimetric assessment. An experimental study on
this particular type of implants will be reported
separately.
Data collection and variables definition
The data obtained from the Swedish National Breast
Cancer Registry, i.e. laterality of cancer, laterality of RT,
reconstruction vs. mastectomy alone, were additionally
verified for each patient in ARIA.
Dose Volume Histograms (DVHs) as well as dose sta-
tistics for ipsilateral lung, heart, and CTV were retrieved
from the system. Ipsilateral lung dosimetry was assessed
using minimum, maximum and mean dose to the lung,
as well as V20Gy. The heart dosimetry was evaluated only
in patients with left-sided breast cancer due to the fact
that irradiation of the heart in the right-sided plans was
negligible. Heart variables included minimum, max-
imum, mean dose and V25Gy.
CTV coverage was defined as percentage of clinical
target volume covered by ≥95% of isodose (CTV V95%).
CTV V95% was evaluated both in the absolute measures
(cm3 covered with 95% of isodose) as well as the relative
measures (% of CTV covered with 95% of isodose).
In order to take into account patients’ rib cage shape,
the following parameters were also considered: internal
transverse diameter (T), measured between the lateral-
most points of the rib cage; anterioposterior diameter
(AP), from the back of the sternum to the front of thevertebra; and hemithorax anterioposterior diameter, be-
tween the anterior-most point and posterior-most point
of the ipsilateral index hemithorax. All measurements
were performed at the mamillary slice of CT scans.
Chest wall index (CWi) was defined as the ratio between
the transverse and the antero-posterior diameter (T/AP)
as suggested by Haller et al. [23].
Statistical analysis
STATA/SE (Version 11.1) for PC and MacOS, Stata-
Corp, TX, USA, was used for all statistical analyses.
Pearson’s chi-square or t-test when appropriate were uti-
lized for assessment of differences in patients with (IBR+)
and without (IBR-) breast reconstruction.
Chest wall, CW (n = 242) and chest wall plus lymph
nodes, CW + LN (n = 576) radiation plans were studied
separately. For the purpose of statistical analysis, the
outcome variables were dichotomized as follows: Lung:
V20Gy ≤ 30% vs. V20Gy >30%; Heart: Dmean ≤5 Gy vs.
Dmean > 5 Gy. In the assessment of heart avoidance, only
left-sided RTPs were used. Univariate and multivariate
regression models were performed to test the association
of outcome variables and potential confounders (breast
reconstruction, side of RT, CW index). The results were
presented as odds ratios (OR) with 95%CI and p-value.
Reported p-values from these models referred to the
Wald-test. A two-tailed p < 0.05 was considered signifi-
cant in all statistical tests.
Ethical approval
This study was approved by the Regional Research
Ethics Committee in Stockholm 2010/1242-31 and
2011/1861 32.
Results
Patients characteristics and planned treatment
From 957 patients who fulfilled the inclusion criteria,
138 women were excluded and the remaining 818 were
included into the study (Figure 1). Table 1 summarizes
patients’ characteristics stratified for immediate breast
Table 1 Demographic and treatment characteristics for 818
patients undergoing mastectomy and receiving
postmastectomy radiotherapy
Total IBR+ IBR-
Characteristics n = 818 (%) n = 162 (%) n = 656 (%) P-value¶
Age at mastectomy, years
Median [min-max] 58 [21-90] 45 [21-69] 58 [21-90] <0.001
≤55 363 (44.4) 136 (84.0) 227 (34.6)
>55 455 (55.6) 26 (16.0) 429 (65.4) <0.001
Calendar year
mastectomy
2009 260 (31.8) 61 (37.7) 199 (30.3)
2010 292 (35.7) 47 (29.0) 245 (37.4)
2011 266 (32.5) 54 (33.3) 212 (32.3) 0.093
Side#
Right 391 (47.8) 90 (55.6) 301 (45.9)
Left 427 (52.2) 72 (44.4) 355 (54.1) 0.027
Tumor size
pT1 309 (37.8) 72 (44.4) 237 (36.1)
pT2 333 (40.7) 57 (35.2) 276 (42.1)
pT3 125 (15.3) 25 (15.4) 100 (15.2) 0.15
Missing* 51 (6.2) 8 (4.9) 43 (6.6)
Lymph nodes
pN0 295 (36.1) 83 (51.2) 212 (32.3)
pN+ 511 (62.5) 77 (47.5) 434 (66.2) <0.001
Missing* 12 (1.5) 2 (1.2) 10 (1.5)
Adjuvant chemotherapy
Yes 388 (47.4) 91 (56.2) 297 (45.3)
No 415 (50.7) 70 (43.2) 345 (52.6) 0.020
Missing* 15 (1.8) 1 (0.6) 14 (2.1)
Neoadjuvant
chemotherapy
No 559 (68.3) 130 (80.2) 429 (65.4)
Yes 259 (31.7) 32 (19.8) 227 (34.6) <0.001
Endocrine therapy
Yes 643 (78.6) 110 (67.9) 533 (81.3)
No 164 (20.1) 49 (30.2) 115 (17.5) <0.001
Missing* 11 (1.3) 3 (1.9) 8 (1.2)
RT target
Chest wall 242 (29.6) 80 (49.4) 162 (24.7)
Chest wall plus lymph
nodes
576 (70.4) 82 (50.6) 494 (75.3) <0.001
Boost dose
Yes 27 (3.3) 3 (1.9) 24 (3.7)
No 791 (96.7) 159 (98.1) 632 (96.3) 0.33
Bolus field
Yes 34 (4.2) 3 (1.9) 31 (4.7)
No 784 (95.8) 159 (98.1) 625 (95.3) 0.12
Table 1 Demographic and treatment characteristics for 818
patients undergoing mastectomy and receiving
postmastectomy radiotherapy (Continued)
Breast implant
Permanent expander 92 (56.8) 92 (56.8) -
Permanent implant 40 (24.7) 40 (24.7) -
Temporary expander
with a magnetic port
30 (18.5) 30 (18.5) - -
IBR indicates immediate breast reconstruction; RT, radiotherapy; pT, tumor size.
*Not included into statistical analysis.
#Including eleven patients with bilateral radiotherapy: IBR + (n= 2) and IBR- (n = 9).
¶Pearson χ2 test.
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struction (IBR-).
Patients’ mean age at the time of mastectomy was 46
years (SD = 8.5) in IBR+ and 58 years (SD = 13.6) in IBR-
subgroups (p < 0.001). In the IBR+ group, patients were
younger (<55 years: 84.0% vs. 34.6%, p < 0.001), neoadju-
vant chemotherapy was given less frequently (19.8% vs.
34.6%, p < 0.001).
The IBR+ subgroup had significantly higher rates of
negative lymph nodes (pN0: 51.2% vs. 32.3%, p < 0.001)
and consequently received RT to regional lymph nodes
less frequently (50.6% vs. 75.3%, p < 0.001). In addition,
this subgroup was treated with adjuvant chemotherapy
and endocrine therapy less frequently (45.3% vs. 56.2%,
p = 0.02 and 67.9% vs. 81.3%, p < 0.001, respectively).Risk organs and clinical target volume dosimetric
evaluation
Dosimetric characteristics of ipsilateral lung stratified for
radiotherapy plan are presented in Table 2. In the chest
wall subset, lung maximum dose was higher in IBR+
group (52.0 vs. 51.4 Gy, p = 0.002).
In the CW+ LN subset, IBR+ patients were signifi-
cantly different from IBR- with regards to lung mean
dose (13.8 vs. 14.3 Gy, p = 0.05) and lung minimum dose
(0.3 vs. 0.2 Gy, p < 0.001).
Heart dosimetry was obtained for 72 IBR+ and 355
IBR- patients with left-sided tumors. No statistically sig-
nificant differences in heart dosimetric characteristics
such as heart V25Gy or mean dose were identified be-
tween the groups (Table 2).
CTV definition in patients with IBR always included
implant that makes the direct dosimetric comparisons
between the groups inaccurate, i.e. CTV was larger in
IBR+ compared to IBR- for both CW (629.4 vs. 458.4 cm3,
p < 0.001) and CW+LN (1074.7 vs. 787.9 cm3, p < 0.001)
radiation plans (Table 3). There was a difference in the rib
cage shape and in the chest wall index between the groups
(Table 3).
Table 2 Dosimetric and anthropometric characteristics* of ipsilateral lung and heart (n = 818)















Volume, cm3 1431.2 [330.2] 1458.6 [318.8] 1417.0 [335.8] 0.36 1369.6 [362.2] 1382.6 [407.7] 1367.4 [354.5] 0.72
Mean dose, Gy 8.9 [3.8] 8.9 [5.2] 8.9 [2.8] 0.96 14.3 [2.1] 13.8 [2.3] 14.3 [2.1] 0.05
Minimum dose, Gy 0.3 [1.0] 0.4 [1.7] 0.2 [0.1] 0.11 0.2 [0.1] 0.3 [0.2] 0.2 [0.1] <0.001
Maximum dose, Gy 51.6 [1.3] 52.0 [1.3] 51.4 [1.3] 0.002 51.8 [1.1] 51.5 [1.5] 51.8 [1.1] 0.06
V20Gy, % 16.4 [6.1] 15.8 [6.0] 16.7 [6.2] 0.30 28.7 [5.3] 28.1 [5.7] 28.8 [5.2] 0.22
Heart‡ n = 118 n = 35 n = 83 n = 309 n = 37 n = 272
Volume, cm3 512.2 [135] 515.9 [115.5] 510.6 [143.0] 0.85 532.2 [117.8] 572.9 [143.1] 526.6 [112.4] 0.024
Mean dose, Gy 3.3 [1.9] 3.0 [0.9] 3.4 [2.1] 0.32 3.5 [1.5] 3.8 [1.2] 3.5 [1.5] 0.29
Minimum dose, Gy 0.2 [0.1] 0.2 [0.1] 0.2 [0.1] 0.25 0.3 [0.2] 0.3 [0.02] 0.3 [0.01] 0.27
Maximum dose, Gy 48.5 [5.5] 48.7 [5.6] 48.4 [5.4] 0.81 47.4 [7.2] 48.5 [5.2] 47.3 [7.5] 0.35
V25Gy, % 3.7 [2.4] 3.1 [1.7] 4.0 [2.7] 0.07 3.8 [2.6] 3.8 [2.1] 3.8 [2.7] 1.0
*All numbers in the rows indicate mean values [standard deviation].
V20Gy indicates volume of the ipsilateral lung irradiated with 20 Gy; V25Gy, volume of heart irradiated with 25 Gy.
‡Calculated for left-sided plans only.
¶Student’s independent t-test.
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The univariate analyses revealed no association between
breast implant reconstruction and ipsilateral lung or
heart dosimetry (Table 4) in neither the chest wall nor
chest wall plus lymph nodes subsets. Among the pos-
sible confounders, only chest wall index was associated







Volume, cm3 629.4 [283.4] 458.4 [273.6]
Mean dose, Gy 50.2 [0.9] 50.7 [4.1]
V95%, %
a 91.2 [5.3] 91.4 [8.4]
V95%, cm
3 b 572.2 [248.9] 417.0 [252.1]
V105%, %
a 10.8 [8.2] 15.3 [12.1]
V105%, cm
3 b 61.0 [37.9] 65.8 [56.6]
Rib cage†
Transverse diameter, cm 23.5 [1.2] 23.5 [1.5]
Anterioposterior diameter, cm 9.5 [1.5] 10.3 [1.5]
Ipsilateral internal diameter, cm 14.2 [1.3] 15.5 [1.6]
Chest wall index 2.5 [0.5] 2.3 [0.4]
*All numbers in the rows indicate mean values [standard deviation].
Radiotherapy plans of patients with temporary expanders containing magnetic por




†Measured at mammillary level tomography slide.to 2.2, p = 0.008). This association remained statistically
significant in multivariate regression adjusting for recon-
struction and side (Table 5).
Type of implant
In the IBR+ subgroup analysis we found no correlation
between the type of implants and the three outcomenical target volume and rib cage (n = 788)






<0.001 1074.7 [263.0] 787.9 [289.0] <0.001
0.31 50.4 [0.6] 50.4 [0.6] 0.97
0.83 93.7 [3.2] 93.3 [4.4] 0.43
<0.001 1006.7 [251.6] 733.9 [270.0] <0.001
0.009 11.8 [6.6] 12.9 [6.1] 0.17
0.55 128.7 [79.6] 104.8 [68.6] 0.007
0.70 24.2 [1.6] 23.4 [1.5] <0.001
<0.001 9.8 [1.3] 10.3 [1.5] 0.006
<0.001 14.6 [1.4] 15.3 [1.6] <0.001
<0.001 2.5 [0.4] 2.3 [0.4] <0.001
ts (n = 30) were excluded from the analyses.
d 105% of isodose.
Table 4 Univariate analysis of lung and heart dosimetry and possible confounders in patients with chest wall only and chest wall plus lymph nodes irradiation
(n = 818)
Chest wall, n = 242 Chest wall plus lymph nodes, n = 576
Lung V20Gy Heart D mean* Lung V20Gy Heart D mean*
Confounders ≤30% >30% OR (95%CI) P-value ≤5Gy >5Gy OR (95%CI) P-value ≤30% >30% OR (95%CI) P-value ≤5Gy >5Gy OR (95%CI) P-value
Reconstruction IBR- 155 7 75 8 293 201 236 36
IBR+ 75 5 1.5 (0.5 to 4.8) 0.52 35 0 -# -# 56 26 0.7 (0.4 to 1.1) 0.13 31 6 1.3 (0.5 to 3.3)
Side Right 118 6 - - 165 102 - -
Left 112 6 1.1 (0.3 to 3.4) 0.93 110 8 - - 184 125 1.1 (0.8 to 1.5) 0.58 267 42 - -
Chest wall index CWi≤med 118 7 57 7 222 119 162 26
CWi > med 112 5 0.8 (0.2 to 2.4) 0.64 53 1 0.2 (0 to 1.3) 0.09 127 108 1.6 (1.1 to 2.2) 0.008 105 16 0.9 (0.5 to 1.9) 0.88
CTV indicates clinical target volume; IBR, immediate breast reconstruction; CWi, chest wall index; med, median.
Lung V20Gy, volume of lung tissue irradiated with 20 Gy (strata: ≤30% vs. >30%); Heart D mean, mean dose delivered to heart (strata: ≤5 Gy vs. >5 Gy);
CTV V95%, percent of clinical target volume irradiated with ≤95% of isodose (strata: ≤median vs. >median).
*Analyzed for patient with left-sided radiation plans (n = 118/242 and n = 309/576).
















Table 5 Multivariate analysis of lung and heart dosimetry and possible confounders in patients with chest wall and
chest wall plus lymph nodes radiotherapy (n = 818)
Chest wall Chest wall plus lymph nodes
n = 242 n = 576
Outcome variable Covariate OR (95%CI) P-value OR (95%CI) P-value
Lung V20Gy
IBR- vs. IBR+ 1.7 (0.5 to 5.8) 0.41 0.6 (0.4 to 1.0) 0.07
Right vs. Left 1.1 (0.3 to 3.4) 0.91 1.1 (0.8 to 1.5) 0.59
CWi≤median vs. CWi >median 0.7 (0.2 to 2.2) 0.50 1.7 (1.2 to 2.3) 0.004
Heart Dmean* n = 118* n = 309*
IBR- vs. IBR+ -# - 1.2 (0.5 to 3.1) 0.72
Right vs. Left - - - -
CWi≤median vs. CWi >median 0.2 (0.3 to 1.8) 0.16 0.9 (0.5 to 1.8) 0.82
IBR, immediate breast reconstruction; CWi, chest wall index; OR, odds ratio; CI, confidence interval.
Lung V20Gy, volume of ipsilateral lung tissue irradiated with 20 Gy (strata: ≤30% vs. >30%); Heart Dmean, mean dose delivered to heart (strata: ≤5 Gy vs. >5 Gy).
*Analyzed for patients with left-sided radiation plans.
#No patients with implant breast reconstruction received >5 Gy to heart.
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ectomy to radiotherapy start among patients with tem-
porary expanders, permanent expanders, permanent
implants, and no reconstruction was 4.5, 4.1, 4.8, and
3.8 months, respectively with no statistically significant
difference (data not shown).
Discussion
In the current study, the presence of a breast implant
during postmastectomy radiotherapy was not associated
with increased doses to ipsilateral lung and heart.
Koutcher et al. were the first to analyze radiotherapy
plans in 41 patients with expandable implants. They re-
ported excellent local control and acceptable heart and
lung doses; 73% patients had adequate chest wall cover-
age, lung V20Gy in the majority of patients was <20% and
mean heart dose was 2.8 Gy. This study, however, is lim-
ited by the small sample size and the absence of a con-
trol group of patients without breast reconstruction [13].
In another publication, radiation plans of a mixed pa-
tient population with autologous tissue reconstruction
from the abdomen (n = 107) and autologous tissue re-
construction from the back +/- implants (n = 5) were
compared with selected controls without IBR (n = 106)
matched by calendar year, side and tumor stage. Using a
novel non-validated scoring system, the authors con-
cluded that more than half of the patients in the IBR+
group had their radiation plans impaired. The coverage
of the chest wall and ipsilateral intramammary nodes,
and dose distribution in the lung were not optimal. The
authors also suggested that in patients with locally ad-
vanced breast cancer, an option for delayed breast recon-
struction should be considered due to potential problems
with radiation delivery [24].A recent case-control study compared 196 patients
having implant-based IBR with 51 matched individuals
without IBR, concluding that having an implant was as-
sociated with lower doses to the lung and non-superior
doses to the heart. Notably, the target volumes for IBR-
plans were not delineated and all ipsilateral lung and
heart structures were delineated for study purposes de
novo. The interpretation of the study results is difficult
due to the fact that different radiation techniques were
utilized in the two disparate groups of IBR+ and IBR- pa-
tients [14].
Another study analyses the impact of inclusion/exclusion
inframammary lymph nodes into CTV in a mix series of
breast implants (n = 10) and autologous tissue reconstruc-
tions (n = 10) [25]. Adequate coverage of reconstructed
breast was demonstrated, regardless of reconstruction type,
laterality and IMN inclusion. This experimental study is
however limited by twenty RTPs and may poses a selection
bias, as it does not include any reference group of patients
without breast reconstruction.
The above studies are not directly comparable with
our study. Firstly, in the current observational cohort
study, all consecutive patients receiving PMRT were in-
cluded and stratified according to breast reconstruction
at a later stage. Secondly, different from other studies
radiotherapy treatment technique (conventional tangen-
tial external-beam radiotherapy with 6-MV photons)
and different calculation algorithm (AAA) were used for
all patients. Thirdly, our definition of target volume is
different from others as we classified radiation plans into
two subsets: chest wall only and chest wall plus lymph
nodes. Finally, irradiation of intramammary nodes that
has been shown to correlate with higher doses to risk or-
gans [14,24] is negligible in our cohort due to the
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targeting. This issue, therefore, was not specifically
addressed in this study.
CTV definition in patients with breast implants is
extremely relevant and will be addressed in the next
study, where we evaluate dosimetric characteristics in
the area outside the implant (“CTV excluding implant”)
being particularly important for the local tumor control.
Furthermore, there are areas irradiated with higher doses
(i.e. V105%) that may have a local influence and affect
cosmesis and morbidity. In the current study, these ex-
cess doses have been seen within the 10-15% of CTV,
however they might be spread along the whole CTV.
These hot spots should be mapped and evaluated as the
possible confounders for negative outcomes of breast
reconstruction.
When assessing possible implications of the implant
type, no significant differences in the OARs dosimetric
characteristics were observed between the three groups.
Interestingly, a difference in rib cage shape between
IBR+ and IBR- groups was found. These differences are
not clear and might be attributed to the age-related
changes in the thorax structure [26]; the clinical applica-
tion of these finding needs to be further explored. We
also found statistically significant differences between
IBR+ and IBR- in the lung mean and minimum dose
(in CW+ LN subset), as well as lung maximum dose
(in CW subset). However, the clinical significance of
these data is doubtful as these endpoint measures do not
take into consideration the volumetric component, i.e.
how large the irradiated lung volume is [10,11].
The strengths of the study include its cohort design
and sample size; consecutive patients were undergoing
PMRT at two radiotherapy units, where the same radi-
ation techniques were utilized regardless breast recon-
struction or not. The actual radiation plans and DVHs
obtained from ARIA hospital-based radiotherapy system,
have been used in the analyses. Assessing the role of
breast implant in the multivariate analysis, we adjusted
for other potential confounding factors, especially intro-
ducing the chest wall index to control for the difference
in the shape of the rib cage.
A weakness of the study might lie in its retrospective
nature as we had a possibility to exclude some patients
from the analyses. We also refrained from CTV dosimet-
ric evaluation in the current study due to the fact that
delineated CTV in IBR+ group always included breast
implant. Mixing these different non-comparable volumes
(i.e. CTVIBR- and CTVIBR+) into one regression model
appeared to be inaccurate and seemed misleading.
In conclusion, current study did not reveal differ-
ences in dose distribution in organs at risk among pa-
tients receiving PMRT with or without breast implants.
Dosimetric characteristics and definition of CTV inpatients with implants urges further evaluation. Further
studies specifically addressing consequences of implants
on PMRT planning and delivery will shed light on onco-
logic safety.
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